Analytical Data
-
Gene name
Claudin-9/CLDN9
- Application
-
Alternative Names
Claudin-9; CLD9
-
Species
Human
-
Source
HEK293
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95484
-
Expression Region
M1-V217
-
Protein Length
Full Length
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Claudin-9 (CLDN9) is a member of the claudin family of proteins, which are essential components of tight junctions in epithelial and endothelial cells. These proteins play a critical role in maintaining the integrity of cell layers, regulating paracellular permeability, and contributing to barrier functions in various tissues. Recent studies have highlighted the significance of CLDN9 in various physiological and pathological processes, including cell adhesion, migration, and signal transduction. Its expression has been linked to certain cancers, where altered tight junction dynamics may facilitate tumor progression and metastasis. Research focusing on CLDN9 recombinant proteins has garnered interest as these proteins offer a valuable tool for elucidating the molecular mechanisms underlying tight junction modulation. By producing and characterizing CLDN9 in a recombinant system, scientists aim to better understand its structural properties, functional interactions, and potential as a therapeutic target. Moreover, recombinant CLDN9 can be used in high-throughput screening assays for drug discovery and to assess the impact of various compounds on tight junction integrity. Understanding the role of CLDN9 in cellular contexts may pave the way for novel therapeutic strategies in diseases characterized by compromised epithelial barriers, such as inflammatory disorders and cancer. Overall, research on CLDN9 recombinant proteins is vital for both basic biology and clinical applications, highlighting the need for continued investigation into their function and potential roles in health and disease.
